Phaeochromocytomas and paragangliomas (PPGLs) are catecholamine secreting neuroendocrine tumours that predispose to haemodynamic instability. Currently, surgery is the only available curative treatment, but carries potential risks including hypertensive and hypotensive crises, cardiac arrhythmias, myocardial infarction and stroke, due to tumoral release of catecholamines during anaesthetic induction and tumour manipulation. The mortality associated with surgical resection of PPGL has significantly improved from 20-45% in the early 20th century (Apgar & Papper, AMA Archives of Surgery, 1951, 62, 634) to 0-2Á9% in the early 21st century (Kinney et al. Journal of Cardiothoracic and Vascular Anesthesia, 2002, 16, 359), largely due to availability of effective pharmacological agents and advances in surgical and anaesthetic practice. However, surgical resection of PPGL still poses significant clinical management challenges. Preoperatively, alpha-adrenoceptor blockade is the mainstay of management, although various pharmacological strategies have been proposed, based largely on reports derived from retrospective data sets. To date, no consensus has been reached regarding the 'ideal' preoperative strategy due, in part, to a paucity of data from high-quality evidence-based studies comparing different treatment regimens. Here, based on the available literature, we address the Clinical Question: Is there an optimal preoperative management strategy for PPGL?
What are the goals of preoperative pharmacological therapy?
At a headline level, normalization of blood pressure and heart rate, and restoration of intravascular fluid status are the main objectives of preoperative pharmacological management. Current guidelines suggest adrenergic blockade should be initiated 7-14 days prior to surgery. 3 However, the average duration of treatment varies depending on the regimen adopted, and whether inpatient or outpatient therapy is initiated. Most centres report an average preoperative treatment duration of 2-6 weeks. 4, 6, 11 Although in some institutions treatment may be started even earlier, there is no evidence to suggest that additional benefit is derived from longer preoperative blockade. 4 Similarly, there is no consensus regarding haemodynamic thresholds that signal adequate blockade, with current published recommendations based largely on noncontrolled studies and institutional experience. Roizen et al. 5 proposed several indicators of adequate preoperative alpha-blockade which included: (i) No in-hospital blood pressure >160/90 mmHg for 24 h prior to surgery; (ii) No orthostatic hypotension with blood pressure <80/45 mmHg; (iii) No ST segment or T wave ECG changes for 1 week prior to surgery; (iv) No more than five premature ventricular contractions per minute. Subsequently, others have suggested a lower preoperative blood pressure (<130/80 mmHg while seated; systolic BP >90 mmHg on standing) and controlled heart rate (60-70 beats per minute while sitting), 6 which align with current Endocrine Society recommendations. 3 However, whether preoperative normalization of systolic blood pressure is mandatory in all patients has been questioned. Lentschener et al. 7 have proposed that only patients with hypertension-induced organ dysfunction require systolic blood pressure normalization prior to surgery, based on their findings that high preoperative systolic BP per se is not predictive of perioperative haemodynamic instability.
functional PPGL who are apparently normotensive and asymptomatic, tumour manipulation may provoke an increase in blood pressure and preoperative medical management is therefore recommended. 3, 8 Preoperative medical treatment may not be required for patients with nonfunctioning (defined by negative metanephrine screening) parasympathetic-derived head and neck paragangliomas or those with exclusive dopamine-secreting tumours. 9 However, intraoperative anaesthetic vigilance and expertise are still required. Preoperative blockade with alpha-adrenoceptor antagonists is also standard care for management of PPGL in pregnancy. Phenoxybenzamine (PBZ) is the preferred agent and is safe for the fetus; however, blood pressure control must be carefully monitored to ensure adequate placental perfusion. 6 The optimal timing for surgical resection of a PPGL during pregnancy is generally considered to be in the second trimester, thereby allowing the pregnancy to progress to normal term/delivery thereafter. However, if this is not possible, then treatment with PBZ should continue until the fetus has reached a satisfactory weight; 2 careful discussion between the patient, endocrinologist, obstetrician and anaesthetist regarding the timing of tumour resection and delivery of the baby by Caesarean section will be required.
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Which preoperative hypotensive drugs have been used?
Alpha-adrenoceptor antagonists
Phenoxybenzamine (PBZ), a noncompetitive a1-and a2-adrenoceptor antagonist, is the most widely used agent for preoperative blockade. Owing to formation of a permanent covalent bond with a-adrenoceptors, PBZ has a long duration of action (t 1/2 = 24 h, which tapers following synthesis of new receptors), and may contribute to sustained hypotension following tumour removal. Side-effects include nasal congestion, CNS sedation, orthostatic hypotension, reflex tachycardia and, at higher doses, paradoxical hypertension. The starting dose is 10 mg twice daily with a recommended maximum daily dose of 1 mg/kg, and average dose requirement of 40-60 mg/day. 10 For the majority of patients, pretreatment with PBZ can be undertaken on an outpatient basis. 11 It is important to note, however, that intraoperative hypertensive surges (systolic blood pressure >160 mmHg) may still occur in patients deemed to be adequately pretreated with PBZ 9 (Fig. 1a,b ). In addition, high cost and restricted availability preclude routine use of PBZ in some centres and countries. 12 Compared with PBZ, selective a 1 -adrenoceptor antagonists such as prazosin, terazosin or urapidil, have short half-lives due to competitive inhibition and displacement by endogenous catecholamines. The shorter half-life of selective a 1 -adrenoceptor antagonists results in less reflex tachycardia and a shorter duration of postoperative hypotension. In contrast, modified release doxazosin has a longer duration of action (t 1/2 = 16-36 h), allowing once daily dosing as well as dose optimization in the days prior to surgery. In general, doxazosin does not cause reflex tachycardia or significant postoperative hypotension.
Several retrospective studies have reported the benefit of preoperative blockade with PBZ using end-points such as operative mortality, intraoperative blood pressure excursions and postoperative complications. 4, [15] [16] [17] There are no published randomized clinical trial data comparing PBZ with selective alpha-blockade. One retrospective study found no difference in blood pressure or intraoperative/postoperative fluid requirements between patients pretreated with PBZ vs doxazosin or prazosin. 18 Another retrospective multicentre study reported higher postoperative inotropic requirements in patients pretreated with PBZ and higher intraoperative blood pressure readings in those who received doxazosin. 19 Evidence for efficacy of selective a 1 -adrenoceptor antagonists in the preoperative management of PPGLs exists mainly for doxazosin (DX). 20, 21 In one study DX performed as well as PBZ with respect to intraoperative haemodynamic stability, with fewer reported side-effects, episodes of intraoperative tachycardia and postoperative fluid requirements, and no difference in mortality. 21 In contrast, other groups observed that pretreatment with DX resulted in higher systolic blood pressures before and after anaesthetic induction compared with PBZ. 23 Van der Zee et al.
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recently reviewed studies comparing pretreatment with PBZ vs DX, and concluded that there was no evidence to suggest superiority of one agent over the other, and that alpha-adrenoceptor blockade per se was efficacious. In another retrospective series, preoperative treatment with prazosin was associated with no deaths, although significant intraoperative hypertensive surges occurred in 83% of treated patients. 21 Successful surgical outcomes following preoperative urapidil administration have also been reported. However, hypertensive surges occurred at induction and/or tumour manipulation in all patients. Esmolol administration was required to control intraoperative tachycardia in one-third of cases. 23 One retrospective study reported no benefit of preoperative alpha-blockade in normotensive patients with secretory PPGL. It is important to note that the number of subjects in the treatment group was almost twice that of the control group and that a modest dose of DX (4 mg) was used in the treatment group. No difference was seen in intraoperative blood pressure in patients treated with DX compared with patients who did not receive alpha-adrenoceptor blockade. There was, however, increased administration of intraoperative inotropes and colloid in the DX-treated group. 25 
Beta-adrenoceptor antagonists
Beta-adrenoceptor antagonists are contraindicated in the absence of effective a 1 -receptor blockade due to the risk of a potentially fatal hypertensive crisis secondary to unopposed alpha-adrenoceptor stimulation. 6 Preoperative use of b-blockers is generally reserved for prevention and treatment of cardiac arrhythmias and reflex tachycardia, and no evidence exists to support the routine use of beta-blockade in the management of noradrenaline-secreting tumours in the absence of arrhythmias. 1 However, preoperative use of b-blockers should be considered in the management of tachycardia or tachyarrhythmias induced by adrenaline-secreting PPGL. Cost and dosing schedules may need to be considered when choosing a beta-adrenoceptor antagonist (the latter to maximize compliance).
Calcium channel antagonists
Calcium channel antagonists (CCB) inhibit noradrenalinemediated calcium influx into vascular smooth muscle thereby inducing coronary and peripheral artery relaxation to control hypertension, tachyarrhythmias and possibly coronary vasospasm. 13 These agents cause minimal hypotension and may be best suited for normotensive patients with paroxysmal hypertension or intolerance to alpha-adrenoceptor antagonists. 6 Brunaud et al. compared patients treated with nircardipine with patients treated with PBZ and beta-blockade and found that intraoperative mean systolic blood pressure and incidence/duration of hypertensive surges was lower in PBZ-treated patients. 25 However, postoperatively, PBZ-treated patients had an increased incidence of hypotension and greater fluid requirements. No difference in overall haemodynamic stability was observed between groups. 25 Similarly, Siddiqi et al. reported no difference in haemodynamic stability between patients treated with either nicardipine or PBZ, although patients pretreated with the former had a smaller mean tumour size and lower metanephrine levels. 26 Finally, in another retrospective series, nicardipine monotherapy was associated with low mortality rates but increased incidence of intraoperative hypertensive episodes. 27 a-methyl-para-tyrosine (Metyrosine)
Metyrosine competitively inhibits tyrosine hydroxylase, the enzyme that regulates the rate-limiting step of catecholamine biosynthesis, 14 to reduce catecholamine levels. Metyrosine is most often used in conjunction with alpha-blockade, and in combination may reduce both intraoperative haemodynamic instability and postoperative cardiovascular morbidity. However, high cost, limited availability and intravenous route of administration restrict routine use. Metyrosine has been reported to provide improved haemodynamic stability and reduced postoperative fluid requirements, although no differences in surgical outcome. [28] [29] [30] It is important to note, however, that hypertensive crises may still occur with metyrosine monotherapy.
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When should add-on therapy be considered?
Add-on therapy should be considered when blood pressure is not adequately controlled with a single agent or the patient is intolerant of escalating doses of monotherapy. In either setting, metyrosine or CCB can be used effectively as add-on therapies to alpha-adrenoceptor antagonists and, in combination, have been found to provide superior haemodynamic stability in some studies. 26, 28 Add-on therapy should also be used to treat tachycardia or cardiac arrhythmias, with beta-adrenoceptor antagonists the preferred agents.
When should preoperative alpha-blockade be discontinued?
Limited data exist to inform this decision and discontinuation of treatment the night prior vs the morning of surgery is guided by the choice of alpha-blockade and half-life of the agent. For example, PBZ has a longer half-life and in patients scheduled for an early morning theatre slot treatment is generally continued until the evening prior to surgery; however, this approach is not universal with some clinicians advising a final dose on the morning of surgery. Where a selective alpha-blocker with a shorter duration of action is used, the last dose is usually administered on the day of surgery.
Do all patients require preoperative fluid replacement?
There is no randomized controlled evidence to support a role for routine preoperative fluid replacement. However, retrospective data suggest that fluid and salt replacement may limit postural hypotension and postoperative hypotension 3 by optimizing intravascular status. If patients are unable to tolerate a high fluid intake orally, administration of intravenous fluids for 24-48 h before surgery is often advised. However, the requirement for preoperative intravenous fluid has been queried, as Lentschener et al. 7 observed no difference in mortality when intravenous fluids were given on an 'as needed' basis only, as guided by arterial blood pressure, indicating that 'prophylactic' administration of intravenous fluids may not improve outcomes in PPGL surgery when appropriate anaesthetic expertise is readily available.
What is the value of perioperative management?
Even when preoperative blockade is carefully managed, and optimal alpha-adrenoceptor blockade and fluid replacement is deemed to have been achieved, intraoperative haemodynamic instability can still occur as illustrated in Fig. 1a,b . Moreover, in some instances, such as emergency surgery in patients with a known phaeochromocytoma, it may not be possible to establish adequate preoperative blockade prior to surgery; however, safe clinical outcomes can still be achieved. Fig. 1c 
Conclusions
There is a lack of available randomized clinical trial data to support decision-making on preoperative management of PPGL. Currently, however, 'PRESCRIPT' (see clinicaltrials.gov), a randomized, multi-centre open label clinical trial is recruiting subjects to determine whether preoperative treatment with PBZ or DX is superior with regards to minimizing intraoperative haemodynamic instability. Until these data are reported, current recommendations and available evidence support PBZ (or, where not available, DX) as first line preoperative pharmacological therapy in patients with PPGLs. In the majority of cases, a short period of preoperative blockade with PBZ, combined with active fluid management, allows surgery to proceed uneventfully. However, even when the patient's clinical status is deemed to have been 'optimized' prior to surgery, significant intraoperative blood pressure excursions may still occur. There is growing evidence that perioperative anaesthetic expertise is critical for successful management of patients with PPGL undergoing surgery, and we believe that this may in fact be the single most important factor governing outcome.
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